The Goldman Sachs Group Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective increased by The Goldman Sachs Group from $36.00 to $41.00 in a research note published on Friday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

A number of other research firms also recently weighed in on TARS. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded down $1.82 on Friday, hitting $44.83. 1,950,213 shares of the stock were exchanged, compared to its average volume of 732,193. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.71 billion, a PE ratio of -11.77 and a beta of 1.00. Tarsus Pharmaceuticals has a one year low of $15.60 and a one year high of $52.99. The firm’s 50 day moving average is $37.84 and its two-hundred day moving average is $32.52.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Swiss National Bank lifted its holdings in shares of Tarsus Pharmaceuticals by 1.4% during the 1st quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after purchasing an additional 600 shares during the last quarter. Alpha DNA Investment Management LLC grew its holdings in shares of Tarsus Pharmaceuticals by 9.1% during the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock worth $412,000 after purchasing an additional 1,261 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Tarsus Pharmaceuticals by 33.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares during the period. Profund Advisors LLC increased its position in shares of Tarsus Pharmaceuticals by 26.8% in the 2nd quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock valued at $248,000 after purchasing an additional 1,929 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth $61,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.